Futures point higher; AMD reports; Novo to cut costs - what’s moving markets
Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, announced today that Asmita Dubey, an Independent (LON:IOG) Non-Executive Director and Person Discharging Managerial Responsibilities (PDMR), has purchased ordinary shares in the company. The transaction took place on the London Stock Exchange (LON:LSEG) (XLON) on Friday.
Dubey acquired a total of 15,424 ordinary shares at a price of £4.01 per share. This information is disclosed in accordance with the UK Market Abuse Regulation, which mandates public notification of transactions by PDMRs.
The purchase is a sign of confidence in the company from one of its directors, reflecting a personal investment in Haleon’s continued success. Haleon’s product portfolio includes well-known brands such as Advil, Centrum, and Sensodyne, covering a range of health categories from oral care to pain relief and vitamins.
This transaction is part of the standard regulatory filings required by the Securities Exchange Act of 1934, which ensures transparency in the financial activities of corporate insiders. The report is signed by Amanda Mellor, Company Secretary of Haleon plc, confirming the details of the transaction.
For more information on Haleon’s product offerings and initiatives, interested parties can visit their official website. The disclosure of this shareholding aligns with Haleon’s commitment to corporate transparency and governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.